Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- NEW PRODUCTS
November 7, 2005
- Drug Companies to Enjoy Good Results in 1st Half
November 7, 2005
- SEMINAR
November 7, 2005
- Eisai Licenses Vaccine Adjuvant to Sanofi Pasteur
November 7, 2005
- Kyorin Licenses OAB Treatment to LG Life Sciences of South Korea
November 7, 2005
- Pharma Industry Has Steadily Increased Added Value: OPIR Report
November 7, 2005
- MREAC to Review MR Certification, Accreditation Systems
November 7, 2005
- BUSINESS NEWS IN BRIEF
November 7, 2005
- Korosho's Healthcare Reform Proposals Criticized by Prefectural Governor
November 7, 2005
- REGULATORY NEWS IN BRIEF
November 7, 2005
- the 6th Kitasato University-Harvard School of Public Health Symposium
November 7, 2005
- Japan Lags Behind Other Countries in Terms of Access to New Drugs: OPIR Report
November 7, 2005
- Strengthen Consultation System to Promote Participation in Int'l Clinical Trials: Dr Doi of PMDA
November 7, 2005
- Requirements Relaxed to Facilitate IITs
November 7, 2005
- Korosho to Fund Research Projects to Improve Clinical Research Infrastructure
November 7, 2005
- JMA Pamphlet Questions Need to Control Healthcare Spending
November 7, 2005
- R&D NEWS IN BRIEF
November 7, 2005
- SURVEY 2 articles
November 7, 2005
- IC Tag Commercialization Research Project Invites Members
November 7, 2005
- BUSINESS NEWS IN BRIEF
October 31, 2005
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…